Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
MORRISTOWN, N.J., May 01, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2018, after the market close on Thursday, May 10, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, May 10 | ||||||||
| Time: | 4:30 PM ET | ||||||||
| Toll free (U.S.): | 888-394-8218 | ||||||||
| International: | 323-701-0225 | ||||||||
| Conference ID: | 7026871 | ||||||||
| Webcast: | http://public.viavid.com/index.php?id=129150 | ||||||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
